Company news

Rani Therapeutics Holdings, Inc. news in 2025

Rani Therapeutics Holdings, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Rani Therapeutics to Participate in the Evercore Healthcare Conference

November 24, 2025

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

November 6, 2025

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

October 30, 2025

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

October 23, 2025

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

October 23, 2025

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

October 17, 2025

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

October 17, 2025

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

August 7, 2025

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

July 15, 2025

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

July 14, 2025

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

March 31, 2025

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

March 26, 2025

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

March 25, 2025

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC

February 4, 2025

Calls in 2025